Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…
The Fidelity Contrafund has released its 2012 annual report for its shareholders. While the date is December 31, 2012, and the asset size is listed as more than $84 billion as of…
Jon OggThese are some of this Monday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Amgen Inc. (NASDAQ: AMGN) cut to Market Perform at William Blair. AOL Inc.…
ThinkstockInvesting in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited pipelines or their very survival depends on a single binary event that…
U.S. equity markets opened higher this morning before dipping following the report on new home sales in the U.S. Stocks regained positive momentum during most of the remaining session. In Europe, Germany’s…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Friday. Alliant Techsystems Inc. (NYSE: ATK) cut to Market Perform at FBR Capital…
U.S. equity markets opened mixed this morning with the DJIA and the S&P 500 higher, and the Nasdaq lower, dragged down by concern over the earnings of Apple Inc. (NASDAQ: AAPL) (more…
U.S. equity markets opened higher this morning following a string of solid earnings reports yesterday and after markets closed last night. As we note below, earnings results were more mixed today, but…
thinkstock Today got off to a bit of a rocky start on earnings. McDonald’s Corp. (NYSE: MCD) beat estimates but not by much and growth appears to be stalled for the world’s…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. Amgen Inc. (NASDAQ: AMGN) cut to Neutral at Credit Suisse. ARM Holdings…
The week ahead will be the official flood gate opening for earnings season. We have a very large portion of the S&P 500 Index reporting fourth-quarter earnings, and we have many Dow Jones…
ThinkstockThe dread and fear that can come with a cancer diagnosis have their roots in its killer nature. It is the number two cause of death in Americans, second only to heart…
ThinkstockCancer ranks on the list of global killers as number two. Over the years, great strides have been made not only in cancer treatment but in survival rates for many different forms of…
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you…
ThinkstockAmgen Inc. (NASDAQ: AMGN) is holding up better than some investors might have expected after the biotech giant warned about earnings. The lowering of earnings estimates was by a mere $0.10 for…
Jon C. Ogg 
